Detalles de la búsqueda
1.
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
Diabetes Obes Metab
; 2024 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38679838
2.
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.
Diabetes Obes Metab
; 25(1): 3-17, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35929488
3.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Lancet
; 398(10295): 143-155, 2021 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34186022
4.
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
Cardiovasc Diabetol
; 21(1): 50, 2022 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35395808
5.
The Effect of Prestudy Insulin Therapy on Safety and Efficacy of Human Regular U-500 Insulin by Pump or Injection: A Posthoc Analysis.
Endocr Pract
; 27(8): 783-789, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33515757
6.
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
Diabetes Obes Metab
; 22(5): 779-787, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31903697
7.
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.
Diabetes Obes Metab
; 22(11): 2199-2203, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32691499
8.
Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
Diabetes Obes Metab
; 21(7): 1634-1641, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30891886
9.
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.
Diabetes Obes Metab
; 21(2): 402-407, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30160030
10.
Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
Diabetes Obes Metab
; 21(3): 622-630, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30362250
11.
Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers.
Clin Diabetes
; 37(4): 368-376, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31660010
12.
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial.
Clin Diabetes
; 37(1): 73-81, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30705500
13.
Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.
Cardiovasc Diabetol
; 17(1): 118, 2018 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30143045
14.
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Diabetes Obes Metab
; 20(1): 165-172, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28685973
15.
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Diabetes Obes Metab
; 20(2): 448-452, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28736942
16.
HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Endocr Pract
; 24(3): 273-287, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29547044
17.
Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.
Clin Diabetes
; 36(2): 149-159, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29686454
18.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Diabetes Obes Metab
; 19(10): 1408-1415, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28386990
19.
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
BMC Endocr Disord
; 17(1): 32, 2017 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28595617
20.
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
JAMA
; 318(1): 45-56, 2017 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28672317